[Proceedings: Tuberculosis therapy. Review on today's knowledge, developmental trends and still open problems].
D000636:Aminosalicylic Acids / Q000627:therapeutic use; D000995:Antitubercular Agents / Q000009:adverse effects / Q000097:blood / Q000378:metabolism / Q000627:therapeutic use*; D002207:Capreomycin / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D004352:Drug Resistance, Microbial; D004977:Ethambutol / Q000627:therapeutic use; D005000:Ethionamide / Q000627:therapeutic use; D005860:Germany, West; D006801:Humans; D007538:Isoniazid / Q000627:therapeutic use; D007902:Length of Stay; D012293:Rifampin / Q000627:therapeutic use; D013307:Streptomycin / Q000627:therapeutic use; D014376:Tuberculosis / Q000188:drug therapy*
D000636:Aminosalicylic Acids; D000995:Antitubercular Agents; D004338:Drug Combinations; D002207:Capreomycin; D004977:Ethambutol; D005000:Ethionamide; D007538:Isoniazid; D012293:Rifampin; D013307:Streptomycin
Therapie der Tuberkulose. Ubersicht über den erreichten Wissensstand, Entwicklungstendenzen und noch offene Probleme.